187 related articles for article (PubMed ID: 24215622)
21. Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant.
Hamada M; Bhakta V; Andres SN; Sheffield WP
Front Cardiovasc Med; 2021; 8():647405. PubMed ID: 33816577
[TBL] [Abstract][Full Text] [Related]
22. Molecular mapping of the thrombin-heparin cofactor II complex.
Fortenberry YM; Whinna HC; Gentry HR; Myles T; Leung LL; Church FC
J Biol Chem; 2004 Oct; 279(41):43237-44. PubMed ID: 15292227
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.
Cooper ST; Rezaie AR; Esmon CT; Church FC
Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592
[TBL] [Abstract][Full Text] [Related]
24. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
Sheehan JP; Tollefsen DM; Sadler JE
J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
[TBL] [Abstract][Full Text] [Related]
25. Serpin-glycosaminoglycan interactions.
Rein CM; Desai UR; Church FC
Methods Enzymol; 2011; 501():105-37. PubMed ID: 22078533
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of thrombin by hirudin genetically fused to wild-type or mutant antithrombin.
Syed S; Kelly KE; Sheffield WP
Thromb Res; 1996 Dec; 84(6):419-29. PubMed ID: 8987163
[TBL] [Abstract][Full Text] [Related]
27. Human thrombin variable region 1, including E39, is involved in interactions with alpha 1-antitrypsin M358R and protein C.
Gaussem P; Picard V; Chadeuf G; Arnaud E; Aiach M
FEBS Lett; 1995 May; 365(2-3):219-22. PubMed ID: 7781782
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease.
Stone SR; Le Bonniec BF
J Mol Biol; 1997 Jan; 265(3):344-62. PubMed ID: 9018048
[TBL] [Abstract][Full Text] [Related]
29. Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity.
Mao SJ; Yates MT; Owen TJ; Krstenansky JL
Biochemistry; 1988 Oct; 27(21):8170-3. PubMed ID: 3233202
[TBL] [Abstract][Full Text] [Related]
30. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II.
Verhamme IM; Bock PE; Jackson CM
J Biol Chem; 2004 Mar; 279(11):9785-95. PubMed ID: 14701814
[TBL] [Abstract][Full Text] [Related]
31. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
Thromb Haemost; 2009 May; 101(5):867-77. PubMed ID: 19404540
[TBL] [Abstract][Full Text] [Related]
32. Altering heparin cofactor II at VAL439 (P6) either impairs inhibition of thrombin or confers elastase resistance.
Cunningham MA; Bhakta V; Sheffield WP
Thromb Haemost; 2002 Jul; 88(1):89-97. PubMed ID: 12152684
[TBL] [Abstract][Full Text] [Related]
33. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI
J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098
[TBL] [Abstract][Full Text] [Related]
34. Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition.
Ciaccia AV; Monroe DM; Church FC
J Biol Chem; 1997 May; 272(22):14074-9. PubMed ID: 9162031
[TBL] [Abstract][Full Text] [Related]
35. Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition.
Mitchell JW; Church FC
J Biol Chem; 2002 May; 277(22):19823-30. PubMed ID: 11856753
[TBL] [Abstract][Full Text] [Related]
36. Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin.
Sheffield WP; Blajchman MA
FEBS Lett; 1995 May; 365(2-3):189-92. PubMed ID: 7781777
[TBL] [Abstract][Full Text] [Related]
37. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
Derechin VM; Blinder MA; Tollefsen DM
J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
[TBL] [Abstract][Full Text] [Related]
38. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes.
Perlmutter DH; Glover GI; Rivetna M; Schasteen CS; Fallon RJ
Proc Natl Acad Sci U S A; 1990 May; 87(10):3753-7. PubMed ID: 2160076
[TBL] [Abstract][Full Text] [Related]
39. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
Blinder MA; Tollefsen DM
J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of heparin cofactor II anticoagulant activity.
Bauman SJ; Church FC
J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
